Our advisory board
Internationally recognized experts from the business and scientific are members of the advisory board of oncgnostics GmbH.
Prof. Dr. Matthias Dürst
Matthias Dürst, a proven expert in the field of human papillomaviruses and carcinogenesis, made significant contributions to the research work that led to Prof. Dr. Harald zur Hausen being awarded the Nobel Prize for Medicine in 2008. The spin-off of oncgnostics from the University Women’s Hospital Jena is based on research work in his laboratory.
Katrin Uschmann
Katrin Uschmann is a proven expert in the financing of life science companies. She has extensive experience in venture capital and private equity as well as corporate finance / equity capital markets. In the course of her more than twenty years at bm-t beteiligungsmanagement thüringen GmbH, she has built up a top-class life science portfolio and supported numerous highly successful exits, including the IPO of InflaRx N.V. on the NASDAQ.
Luxiang Cheng
Luxiang Cheng supports oncgnostics GmbH with his many years of experience in the field of diagnostics, particularly in China. He currently manages Shanghai GeneoDx, a cooperation partner of oncgnostics, as well as Pathofinder BV in Maastricht, Netherlands.
Dr. Christoph Petry
Christoph Petry has many years of experience in the diagnostics industry. With a doctorate in chemistry, he was Head of Molecular Research Germany at Bayer HealthCare Diagnostics and later held the same position at Siemens Healthcare Diagnostics. As founder and CEO of Sividon Diagnostics, he led the company until its successful exit with Myriad Genetics in 2016. He then restructured m2p-labs GmbH as Managing Director until its lucrative sale to Beckman Coulter in 2020.
Eugen Ermantraut
Eugen Ermantraut is himself a successful founder in the medical technology sector. He founded Clondiag GmbH in Jena, which was acquired by Inverness Medical Innovations in 2006. After changing its name to Alere Technologies, it was sold to Abbott in 2016. Ermantraut subsequently founded Blink AG, which specializes in innovative PCR-based point-of-care systems.